Drugmaker Roche's new rare disease treatment is letting it edge its way into an exclusive but lucrative $10 billion global market

Nederland Nieuws Nieuws

Swiss drugmaker Roche is breaking into hemophilia A treatment, a $10 billion global market dominated by rivals who have cultivated close ties to their patients. Roche's drug, Hemlibra, available since late 2017, is expected to receive a nod from the FDA for use in nearly all patients this week.